/

XLO

Xilio Therapeutics, Inc.After hours

9.22+0.15 +1.60%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

9.05

Prev close

9.08

Day range

8.869.22

52-week range

6.4712.59

Volume

17.74K0.99×

Mkt cap

60.67M

P/E ttm

—

Fwd P/E

-15.90

EPS ttm

-0.6000

Div yield

0.00%

Earnings

—

From 52w high

−26.74%

Price Chart

Yahoo Finance · delayed

XLOOct 13, 2026O 9.05H 9.22L 8.85C 9.22+0.15 (+1.60%)Vol 17.74K

SMA 509.07
SMA 2008.57

1Y change −17.06% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

XLO Xilio Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.44%
1 month: +3.25%
3 months: +2.10%
6 months: +7.33%
Year to date: +2.90%
1 year: −15.13%

Valuation & ownership

Market cap: 60.67M
Enterprise value: −70.02M
P/E (ttm): —
Forward P/E: -15.90
PEG ratio: —
Price / book: 0.84
Price / sales (ttm): 0.95
EV / EBITDA: 2.33
EPS (ttm): -0.6000
EPS (forward): -0.5800
Beta (5y monthly): -0.12
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 6.58M
Float: 3.40M
Short % of float: 6.96%
Short ratio (days): 38.99
Held by insiders: 25.98%
Held by institutions: 50.16%
Avg volume (3m): 17.87K
50-day average: 9.07
200-day average: 8.57
52-week change: −15.13%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 59.9
vs 50-day SMA: +1.66%
vs 200-day SMA: +7.55%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.54%
Realised vol (20d, ann.): 15.1%
From 52-week high: −26.74%
From 52-week low: +42.55%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

20.00

+116.92% implied

Low 20.00Median 20.00High 20.00

Recommendation trend

Now1 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →trailing twelve months

DES

About Xilio Therapeutics, Inc.

Yahoo Finance profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 76
Headquarters: Waltham, MA, United States
Website: xiliotx.com
Officers: Dr. Rene Russo BCPS, Pharm.D. President, CEO & Director
Mr. Christopher Frankenfield CFO & COO
Mr. Kevin M. Brennan Senior Vice President of Finance & Accounting
Dr. Uli Bialucha Ph.D. Chief Scientific Officer

SEAS

Seasonality · XLO

2021–2026 · monthly returns

Strongest month Oct +9.98%Weakest month Jun −16.36%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-7.0	-11.3	13.8	-5.8	6.8	13.2	-4.9	-1.8	1.1	1.9			+2.9%
2025	-26.2	28.5	-20.1	5.8	39.7	-36.4	-4.6	7.9	20.4	-5.5	-4.9	-15.6	−33.0%
2024	18.2	9.1	52.3	-3.7	3.8	-12.2	0.2	-9.7	-8.2	61.2	-14.2	-12.4	+73.6%
2023	35.7	-1.1	-12.2	4.1	-7.6	-14.1	9.2	0.3	-26.5	3.8	-58.9	-38.9	−79.6%
2022	-14.9	-13.4	-40.0	-50.1	-15.0	-2.7	-0.7	-22.8	29.9	-19.6	3.4	11.2	−83.2%
2021											-5.7	1.0	−4.7%

INSD

Insider Activity · XLO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

2.73M shares

Sells, 6 months

5.2K shares

Net shares

+2.73M

Net change in insider shares

−267.90%

Date	Insider	Transaction	Shares	Value
Mar 25, 2026	Shannon James SamuelDirector	Purchase at price 8.79 per share.	5K	$43.95K
Jan 1, 2026	Brennan Kevin MOfficer	Sale at price 0.64 per share.	1.8K	$1.17K
Jan 1, 2026	Frankenfield Christopher JamesChief Financial Officer	Sale at price 0.64 per share.	7K	$4.52K
Dec 30, 2025	Russo Rene Pharm.D.Chief Executive Officer	—	44.3K	—
Dec 30, 2025	Brennan Kevin MOfficer	—	5K	—
Dec 30, 2025	Frankenfield Christopher JamesChief Financial Officer	—	19.4K	—
Dec 30, 2025	Luptakova Katarina M.D.Officer	—	16.6K	—
Nov 25, 2025	Gilead Sciences IncBeneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 0.75 per share.	13.34M	$10.00M
Jun 16, 2025	Shannon James SamuelDirector	Purchase at price 0.69 per share.	70K	$48.09K
Jun 15, 2025	Russo Rene Pharm.D.Chief Executive Officer	Purchase at price 0.68 per share.	36.3K	$24.68K
Jan 1, 2025	Brennan Kevin MOfficer	Sale at price 0.98 per share.	1.8K	$1.77K
Jan 1, 2025	Frankenfield Christopher JamesChief Financial Officer	Sale at price 0.98 per share.	7K	$6.84K
Dec 30, 2024	Russo Rene Pharm.D.Chief Executive Officer	—	44.3K	—
Dec 30, 2024	Russo Rene Pharm.D.Chief Executive Officer	—	44.3K	—
Dec 30, 2024	Brennan Kevin MOfficer	—	5K	—
Dec 30, 2024	Frankenfield Christopher JamesChief Financial Officer	—	19.4K	—
Dec 30, 2024	Luptakova Katarina M.D.Officer	—	16.6K	—
Dec 17, 2024	Gilead Sciences IncBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.04 per share.	1.76M	$1.83M

13F

Investors Holding XLO

latest 13F filings of 29 followed managers

Investors holding XLO
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$614.6K	0.00%	64.15K	+29%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

XLO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

XLO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Xilio Therapeutics, Inc.

Seasonality · XLO

Insider Activity · XLO

Congress Trades · XLO

Investors Holding XLO

Investors Holding XLO

Congress Trades · XLO

Insider Activity · XLO

Seasonality · XLO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Xilio Therapeutics, Inc.

Earnings & Dividends

News